Whanin Pharm Market Cap ($130.27 Million)
Market Cap & Net Worth: Whanin Pharm (016580)
Whanin Pharm market cap. Whanin Pharm (KO:016580) has a market capitalization of $130.27 Million (₩192.23 Billion) as of November 1, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18023 globally and #774 in its home market, demonstrating a 1.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Whanin Pharm's stock price ₩10400.00 by its total outstanding shares 18483950 (18.48 Million). Also see 016580 cash flow conversion for how efficiently the company converts equity into cash flow.
Whanin Pharm Market Cap History (2015–2026)
Whanin Pharm market cap history from 2015 to 2026. Data shows change from $213.16 Million to $130.27 Million (-4.48% CAGR). Check 016580 stock price and chart for real-time trading data and today's change.
Whanin Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Whanin Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Whanin Pharm net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Whanin Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Whanin Pharm's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $175.58 Million | $141.38 Billion | $16.40 Billion | 0.00x | 0.01x |
| 2017 | $249.93 Million | $147.95 Billion | $27.17 Billion | 0.00x | 0.01x |
| 2018 | $218.66 Million | $154.66 Billion | $21.52 Billion | 0.00x | 0.01x |
| 2019 | $179.90 Million | $159.18 Billion | $18.70 Billion | 0.00x | 0.01x |
| 2020 | $198.05 Million | $171.71 Billion | $23.39 Billion | 0.00x | 0.01x |
| 2021 | $214.75 Million | $177.78 Billion | $26.66 Billion | 0.00x | 0.01x |
| 2022 | $216.03 Million | $198.93 Billion | $23.92 Billion | 0.00x | 0.01x |
| 2023 | $188.40 Million | $230.39 Billion | $29.77 Billion | 0.00x | 0.01x |
| 2024 | $147.94 Million | $259.60 Billion | $23.38 Billion | 0.00x | 0.01x |
| 2025 | $141.80 Million | $255.21 Billion | $13.60 Billion | 0.00x | 0.01x |
Competitor Companies of 016580 by Market Capitalization
Companies near Whanin Pharm in the global market cap rankings as of November 1, 2026. Also see 016580 total asset value for a full breakdown of the balance sheet.
Key companies related to Whanin Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Whanin Pharm (2015–2026)
Market capitalization of Whanin Pharm from 2015 to today. Between 2015 and today, Whanin Pharm's market cap moved from $213.16 Million to $ 130.27 Million, with a yearly change of -4.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩130.27 Million | -8.13% |
| 2025 | ₩141.80 Million | -4.15% |
| 2024 | ₩147.94 Million | -21.48% |
| 2023 | ₩188.40 Million | -12.79% |
| 2022 | ₩216.03 Million | +0.60% |
| 2021 | ₩214.75 Million | +8.43% |
| 2020 | ₩198.05 Million | +10.09% |
| 2019 | ₩179.90 Million | -17.73% |
| 2018 | ₩218.66 Million | -12.51% |
| 2017 | ₩249.93 Million | +42.34% |
| 2016 | ₩175.58 Million | -17.63% |
| 2015 | ₩213.16 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Whanin Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $130.27 Million USD |
| MoneyControl | $130.27 Million USD |
| MarketWatch | $130.27 Million USD |
| marketcap.company | $130.27 Million USD |
| Reuters | $130.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more